Epysqli®
ACTIVE PRINCIPLE:
eculizumab
INDICATION:
paroxysmal hemoglobinuria
DATE:
26/05/2023
STATUS:
Authorized
Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE:
eculizumab
INDICATION:
paroxysmal hemoglobinuria
DATE:
26/05/2023
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.